+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nasal Antihistamines Market Forecast, Trend Analysis & Opportunity Assessment 2021-2031

  • PDF Icon

    Report

  • 250 Pages
  • October 2021
  • Region: Global
  • Future Market Insights
  • ID: 5509580
A recent market study by this publisher on the nasal antihistamines market offers a global industry analysis for 2016-2020 and an opportunity assessment for 2021-2031. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the nasal antihistamines market, growth prospects of the market are obtained with maximum precision.
The report features unique and salient factors that may make a huge impact on the development of the nasal antihistamines market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in this market in the coming years.
The report provides detailed information about the current and future growth prospects of nasal antihistamines market in the most comprehensive way for better understanding of readers.

Key Segments of Nasal Antihistamines Market

Future Market Insight study on the nasal antihistamines market offers information divided into five important segments - product, age group, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Product


  • Nasal Spray
  • Nasal Drops

Age Group

  • Adult
  • Paediatric

Distribution Channel


  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Stores

Region


  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope/Limitations
2.3. Inclusion and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Method Innovation/Development Trends
4. Market Background
4.1. Macro-Economic Factors
4.1.1. Global Gdp Growth Outlook
4.1.2. Global Healthcare Expenditure Outlook
4.1.3. Parent Market Outlook
4.2. Forecast Factors - Relevance & Impact
4.2.1. Rising Adoption of Nasal Antihistamines
4.2.2. Cost of Product
4.2.3. Number of Local Manufacturers
4.2.4. Increasing Drug Discovery Activities
4.2.5. R&D Spending
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Trends
4.3.4. Opportunity Analysis
5. COVID19 Crisis Analysis
5.1. Current COVID19 Probable Future Impact
5.2. Current Gdp Projection and Probable Impact
5.3. Current Economic Projection as Compared to 2008 Economic Analysis
5.4. COVID19 and Impact Analysis
5.4.1. Revenue by Dosage Form
5.4.2. Revenue by Age Group
5.4.3. Revenue by End-user
5.4.4. Revenue by Country
5.5. 2020 Market Scenario
5.6. Recovery Scenario - Short Term, Midterm and Long Term Impact
6. Key Success Factors
6.1. Adoption/Usage Analysis
6.2. Strategic Promotional Strategies, by Key Manufacturers
6.3. Regulatory Scenario
6.4. Disease Epidemiology
6.5. Patient Treatment Journey
6.6. Pipeline Assessment
6.7. Treatment Cost Analysis
6.8. Value Chain Analysis
7. Global Nasal Histamines Market Demand (In Volume ‘000 Units) Analysis 2016-2020 and Forecast, 2021-2031
7.1. Historical Market Volume (‘000 Units) Analysis, 2016-2020
7.2. Current and Future Market Volume (‘000 Units) Projections, 2021-2031
7.2.1. Y-O-Y Growth Trend Analysis
8. Global Nasal Histamines Market - Pricing Analysis
8.1. Regional Pricing Analysis, by Product Type
8.2. Global Average Pricing Analysis Benchmark
9. Global Nasal Histamines Market Value (Us$ Mn) Analysis 2016-2020 and Forecast, 2021-2031
9.1. Historical Market Value (Us$ Mn) Analysis, 2016-2020
9.2. Current and Future Market Value (In Value or Size in US Mn) Projections, 2021-2031
9.2.1. Y-O-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
10. Global Nasal Histamines Market Analysis 2016-2020 and Forecast 2021-2031, by Dosage Form
10.1. Introduction/Key Findings
10.2. Historical Market Size (In Value or Size in US Mn) Trend by Dosage Form, 2016-2020
10.3. Current and Future Market Size (In Value or Size in US Mn) Trend Analysis and Forecast by Dosage Form , 2021-2031
10.3.1. Sprays
10.3.2. Drops
10.4. Market Attractiveness Analysis by Dosage Form
11. Global Nasal Antihistamines Market Analysis 2016-2020 and Forecast 2021-2031, by Age Group
11.1. Introduction/Key Findings
11.2. Historical Market Size (In Value or Size in US Mn) Trend by Age Group, 2016-2020
11.3. Current and Future Market Size (In Value or Size in US Mn) Trend Analysis and Forecast by Age Group, 2021-2031
11.3.1. Infants
11.3.2. Paediatric
11.3.3. Geriatric
11.4. Market Attractiveness Analysis by Application
12. Global Cholangiocarcinoma Treatment Market Analysis 2016-2020 and Forecast 2021-2031, by Distribution Channel
12.1. Introduction/Key Findings
12.2. Historical Market Size (In Value or Size in US Mn) Trend by Distribution Channel, 2016-2020
12.3. Current and Future Market Size (In Value or Size in US Mn) Trend Analysis and Forecast by Distribution Channel , 2021-2031
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Drug Stores
12.3.4. Online Stores
12.4. Market Attractiveness Analysis by Distribution Channel
13. Global Nasal Antihistamines Market Analysis 2016-2020 and Forecast 2021-2031, by Region
13.1. Introduction
13.2. Historical Market Size (In Value or Size in US Mn) Analysis by Region, 2016 - 2020
13.3. Current Market Size (In Value or Size in US Mn) Analysis and Forecast by Region, 2021 - 2031
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. South Asia
13.3.5. East Asia
13.3.6. Oceania
13.3.7. Middle East and Africa (Mea)
13.4. Market Attractiveness Analysis by Region
14. North America Nasal Antihistamines Market Analysis 2016-2020 and Forecast 2021-2031
14.1. Introduction
14.2. Historical Market Size (In Value or Size in US Mn) Trend Analysis by Market Taxonomy, 2016-2020
14.3. Current and Future Market Size (In Value or Size in US Mn) Trend Analysis Forecast by Market Taxonomy, 2021-2031
14.3.1. by Country
14.3.1.1. U.S.
14.3.1.2. Canada
14.3.2. by Dosage Form
14.3.3. by Age Group
14.3.4. by Distribution Channel
14.4. Market Attractiveness Analysis
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
15. Latin America Nasal Antihistamines Market Analysis 2016-2020 and Forecast 2021-2031
15.1. Introduction
15.2. Historical Market Size (In Value or Size in US Mn) Trend Analysis by Market Taxonomy, 2016 - 2020
15.3. Current and Future Market Size (In Value or Size in US Mn) Trend Analysis Forecast by Market Taxonomy, 2021-2031
15.3.1. by Country
15.3.1.1. Brazil
15.3.1.2. Mexico
15.3.1.3. Argentina
15.3.1.4. Rest of Latin America
15.3.2. by Dosage Form
15.3.3. by Age Group
15.3.4. by Distribution Channel
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
16. Europe Nasal Antihistamines Market Analysis 2016-2020 and Forecast 2021-2031
16.1. Introduction
16.2. Historical Market Size (In Value or Size in US Mn) Trend Analysis by Market Taxonomy, 2016-2020
16.3. Current and Future Market Size (In Value or Size in US Mn) Trend Analysis Forecast by Market Taxonomy 2021-2031
16.3.1. by Country
16.3.1.1. Germany
16.3.1.2. Italy
16.3.1.3. France
16.3.1.4. U.K.
16.3.1.5. Spain
16.3.1.6. Benelux
16.3.1.7. Russia
16.3.1.8. Rest of Europe
16.3.2. by Dosage Form
16.3.3. by Age Group
16.3.4. by Distribution Channel
16.4. Market Attractiveness Analysis
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
17. South Asia Nasal Antihistamines Market Analysis 2016-2020 and Forecast 2021-2031
17.1. Introduction
17.2. Historical Market Size (In Value or Size in US Mn) Trend Analysis by Market Taxonomy, 2016-2020
17.3. Current and Future Market Size (In Value or Size in US Mn) Trend Analysis by Market Taxonomy2021-2031
17.3.1. by Country
17.3.1.1. India
17.3.1.2. Thailand
17.3.1.3. Indonesia
17.3.1.4. Malaysia
17.3.1.5. Rest of South Asia
17.3.2. by Dosage Form
17.3.3. by Age Group
17.3.4. by Distribution Channel
17.4. Market Attractiveness Analysis
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
18. East Asia Nasal Antihistamines Market Analysis 2016-2020 and Forecast 2021-2031
18.1. Introduction
18.2. Historical Market Size (In Value or Size in US Mn) Trend Analysis by Market Taxonomy, 2016-2020
18.3. Current and Future Market Size (In Value or Size in US Mn) Trend Analysis by Market Taxonomy, 2021-2031
18.3.1. by Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.2. by Dosage Form
18.3.3. by Age Group
18.3.4. by Distribution Channel
18.4. Market Attractiveness Analysis
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
19. Oceania Nasal Antihistamines Market Analysis 2016-2020 and Forecast 2021-2031
19.1. Introduction
19.2. Historical Market Size (In Value or Size in US Mn) Trend Analysis by Market Taxonomy, 2016-2020
19.3. Current and Future Market Size (In Value or Size in US Mn) Trend Analysis by Market Taxonomy, 2021-2031
19.3.1. by Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. by Dosage Form
19.3.3. by Age Group
19.3.4. by Distribution Channel
19.4. Market Attractiveness Analysis
19.5. Key Market Participants - Intensity Mapping
19.6. Drivers and Restraints - Impact Analysis
20. Middle East and Africa Nasal Antihistamines Market Analysis 2016-2020 and Forecast 2021-2031
20.1. Introduction
20.2. Historical Market Size (In Value or Size in US Mn) Trend Analysis by Market Taxonomy, 2016-2020
20.3. Current and Future Market Size (In Value or Size in US Mn) Trend Analysis by Market Taxonomy, 2021-2031
20.3.1. by Country
20.3.1.1. Gcc Countries
20.3.1.2. Turkey
20.3.1.3. South Africa
20.3.1.4. Rest of Middle East and Africa
20.3.2. by Dosage Form
20.3.3. by Age Group
20.3.4. by Distribution Channel
20.4. Market Attractiveness Analysis
20.5. Key Market Participants - Intensity Mapping
20.6. Drivers and Restraints - Impact Analysis
21. Key Countries Nasal Antihistamines Market Analysis 2021 & 2031
21.1. U.S. Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.1.1. by Dosage Form
21.1.2. by Age Group
21.1.3. by Distribution Channel
21.2. Canada Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.2.1. by Dosage Form
21.2.2. by Age Group
21.2.3. by Distribution Channel
21.3. Brazil Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.3.1. by Dosage Form
21.3.2. by Age Group
21.3.3. by Distribution Channel
21.4. Mexico Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.4.1. by Dosage Form
21.4.2. by Age Group
21.4.3. by Distribution Channel
21.5. Argentina Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.5.1. by Dosage Form
21.5.2. by Age Group
21.5.3. by Distribution Channel
21.6. U.K. Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.6.1. by Dosage Form
21.6.2. by Age Group
21.6.3. by Distribution Channel
21.7. Germany Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.7.1. by Dosage Form
21.7.2. by Age Group
21.7.3. by Distribution Channel
21.8. France Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.8.1. by Dosage Form
21.8.2. by Age Group
21.8.3. by Distribution Channel
21.9. Italy Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.9.1. by Dosage Form
21.9.2. by Age Group
21.9.3. by Distribution Channel
21.10. Spain Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.10.1. by Dosage Form
21.10.2. by Age Group
21.10.3. by Distribution Channel
21.11. Benelux Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.11.1. by Dosage Form
21.11.2. by Age Group
21.11.3. by Distribution Channel
21.12. Russia Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.12.1. by Dosage Form
21.12.2. by Age Group
21.12.3. by Distribution Channel
21.13. India Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.13.1. by Dosage Form
21.13.2. by Age Group
21.13.3. by Distribution Channel
21.14. Asean Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.14.1. by Dosage Form
21.14.2. by Age Group
21.14.3. by Distribution Channel
21.15. Japan Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.15.1. by Dosage Form
21.15.2. by Age Group
21.15.3. by Distribution Channel
21.16. China Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.16.1. by Dosage Form
21.16.2. by Age Group
21.16.3. by Distribution Channel
21.17. South Korea Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.17.1. by Dosage Form
21.17.2. by Age Group
21.17.3. by Distribution Channel
21.18. Australia Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.18.1. by Dosage Form
21.18.2. by Age Group
21.18.3. by Distribution Channel
21.19. New Zealand Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.19.1. by Dosage Form
21.19.2. by Age Group
21.19.3. by Distribution Channel
21.20. Gcc Countries Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.20.1. by Dosage Form
21.20.2. by Age Group
21.20.3. by Distribution Channel
21.21. Turkey Nasal Antihistamines Market Value (Us$) Analysis, 2021 & 2031
21.21.1. by Dosage Form
21.21.2. by Age Group
21.21.3. by Distribution Channel
21.22. South Africa Nasal Antihistamines Market Value (Us$) and Analysis, 2021 & 2031
21.22.1. by Dosage Form
21.22.2. by Age Group
21.22.3. by Distribution Channel
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Concentration
22.3. Market Share Analysis of Top Players
22.4. Market Presence Analysis
22.4.1.1. Regional Footprint of Players
22.4.1.2. Method Foot Print by Players
22.4.1.3. Channel Foot Print by Players
23. Competition Analysis
23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Competition Deep Dive
23.3.1. Bayer Healthcare
23.3.1.1. Overview
23.3.1.2. Product Portfolio
23.3.1.3. Profitability by Market Segments (Product/End-user/Region)
23.3.1.4. Sales Footprint
23.3.1.5. Strategy Overview
23.3.1.5.1. Marketing Strategy
23.3.1.5.2. Product Strategy
23.3.1.5.3. End-user Strategy
23.3.2. Merck & Co Inc.
23.3.2.1. Overview
23.3.2.2. Product Portfolio
23.3.2.3. Profitability by Market Segments (Product/End-user/Region)
23.3.2.4. Sales Footprint
23.3.2.5. Strategy Overview
23.3.2.5.1. Marketing Strategy
23.3.2.5.2. Product Strategy
23.3.2.5.3. End-user Strategy
23.3.3. Zicam LLC
23.3.3.1. Overview
23.3.3.2. Product Portfolio
23.3.3.3. Profitability by Market Segments (Product/End-user/Region)
23.3.3.4. Sales Footprint
23.3.3.5. Strategy Overview
23.3.3.5.1. Marketing Strategy
23.3.3.5.2. Product Strategy
23.3.3.5.3. End-user Strategy
23.3.4. J Pharmaceuticals
23.3.4.1. Overview
23.3.4.2. Product Portfolio
23.3.4.3. Profitability by Market Segments (Product/End-user/Region)
23.3.4.4. Sales Footprint
23.3.4.5. Strategy Overview
23.3.4.5.1. Marketing Strategy
23.3.4.5.2. Product Strategy
23.3.4.5.3. End-user Strategy
23.3.5. Meda Pharmaceuticals (Viatris Inc)
23.3.5.1. Overview
23.3.5.2. Product Portfolio
23.3.5.3. Profitability by Market Segments (Product/End-user/Region)
23.3.5.4. Sales Footprint
23.3.5.5. Strategy Overview
23.3.5.5.1. Marketing Strategy
23.3.5.5.2. Product Strategy
23.3.5.5.3. End-user Strategy
23.3.6. Ascend Laboratories LLC
23.3.6.1. Overview
23.3.6.2. Product Portfolio
23.3.6.3. Profitability by Market Segments (Product/End-user/Region)
23.3.6.4. Sales Footprint
23.3.6.5. Strategy Overview
23.3.6.5.1. Marketing Strategy
23.3.6.5.2. Product Strategy
23.3.6.5.3. End-user Strategy
23.3.7. Cvs Health
23.3.7.1. Overview
23.3.7.2. Product Portfolio
23.3.7.3. Profitability by Market Segments (Product/End-user/Region)
23.3.7.4. Sales Footprint
23.3.7.5. Strategy Overview
23.3.7.5.1. Marketing Strategy
23.3.7.5.2. Product Strategy
23.3.7.5.3. End-user Strategy
23.3.8. Altaire Pharmaceuticals
23.3.8.1. Overview
23.3.8.2. Product Portfolio
23.3.8.3. Profitability by Market Segments (Product/End-user/Region)
23.3.8.4. Sales Footprint
23.3.8.5. Strategy Overview
23.3.8.5.1. Marketing Strategy
23.3.8.5.2. Product Strategy
23.3.8.5.3. End-user Strategy
23.3.9. Vicks
23.3.9.1. Overview
23.3.9.2. Product Portfolio
23.3.9.3. Profitability by Market Segments (Product/End-user/Region)
23.3.9.4. Sales Footprint
23.3.9.5. Strategy Overview
23.3.9.5.1. Marketing Strategy
23.3.9.5.2. Product Strategy
23.3.9.5.3. End-user Strategy
23.3.10. Novartis
23.3.10.1. Overview
23.3.10.2. Product Portfolio
23.3.10.3. Profitability by Market Segments (Product/End-user/Region)
23.3.10.4. Sales Footprint
23.3.10.5. Strategy Overview
23.3.10.5.1. Marketing Strategy
23.3.10.5.2. Product Strategy
23.3.10.5.3. End-user Strategy
23.3.11. GlaxoSmithKline plc
23.3.11.1. Overview
23.3.11.2. Product Portfolio
23.3.11.3. Profitability by Market Segments (Product/End-user/Region)
23.3.11.4. Sales Footprint
23.3.11.5. Strategy Overview
23.3.11.5.1. Marketing Strategy
23.3.11.5.2. Product Strategy
23.3.11.5.3. End-user Strategy
23.3.12. Cipla
23.3.12.1. Overview
23.3.12.2. Product Portfolio
23.3.12.3. Profitability by Market Segments (Product/End-user/Region)
23.3.12.4. Sales Footprint
23.3.12.5. Strategy Overview
23.3.12.5.1. Marketing Strategy
23.3.12.5.2. Product Strategy
23.3.12.5.3. End-user Strategy
23.3.13. Sun Pharmaceuticals
23.3.13.1. Overview
23.3.13.2. Product Portfolio
23.3.13.3. Profitability by Market Segments (Product/End-user/Region)
23.3.13.4. Sales Footprint
23.3.13.5. Strategy Overview
23.3.13.5.1. Marketing Strategy
23.3.13.5.2. Product Strategy
23.3.13.5.3. End-user Strategy
23.3.14. Sato Pharmaceutical
23.3.14.1. Overview
23.3.14.2. Product Portfolio
23.3.14.3. Profitability by Market Segments (Product/End-user/Region)
23.3.14.4. Sales Footprint
23.3.14.5. Strategy Overview
23.3.14.5.1. Marketing Strategy
23.3.14.5.2. Product Strategy
23.3.14.5.3. End-user Strategy
23.3.15. Centaur Pharmaceuticals
23.3.15.1. Overview
23.3.15.2. Product Portfolio
23.3.15.3. Profitability by Market Segments (Product/End-user/Region)
23.3.15.4. Sales Footprint
23.3.15.5. Strategy Overview
23.3.15.5.1. Marketing Strategy
23.3.15.5.2. Product Strategy
23.3.15.5.3. End-user Strategy
23.3.16. Glenmark
23.3.16.1. Overview
23.3.16.2. Product Portfolio
23.3.16.3. Profitability by Market Segments (Product/End-user/Region)
23.3.16.4. Sales Footprint
23.3.16.5. Strategy Overview
23.3.16.5.1. Marketing Strategy
23.3.16.5.2. Product Strategy
23.3.16.5.3. End-user Strategy
24. Assumptions and Acronyms Used25. Research Methodology

Companies Mentioned

  • Bayer Healthcare LLC
  • Novartis AG
  • Glenmark Pharmaceuticals
  • GlaxoSmithKline
  • Sun Pharmaceuticals
  • Cipla
  • Merck & Co.
  • Viatris (Meda Pharmaceuticals)
  • Proctor & Gamble
  • Ascend Laboratories LLC (Alkem Laboratories)
  • Centaur Pharmaceuticals
  • J Pharmaceuticals
  • Alitair Pharmaceuticals
  • Sato Pharmaceuticals